Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.

Viruses - 12 Jul 2021

Trombetta Claudia Maria, Marchi Serena, Viviani Simonetta, Manenti Alessandro, Benincasa Linda, Ruello Antonella, Bombardieri Emilio, Vicenti Ilaria, Zazzi Maurizio, Montomoli Emanuele

Abstract excerpt

The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Vaccines

Share to Pandemics

Share to South Africa

Share to Spike Glycoprotein, Coronavirus

Share to Vaccination

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34372553
DOI: 10.3390/v13071347
PMCID: PMC8310013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.PMID 34372553Read ↗

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccinationSemantic proximity Read ↗

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesSemantic proximity Read ↗

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.Semantic proximity Read ↗

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.Semantic proximity Read ↗

Novel SARS-CoV-2 variants: the pandemics within the pandemic.Semantic proximity Read ↗

Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variantsSemantic proximity Read ↗

Humoral immune response of patients infected by earlier lineages of SARS-CoV-2 neutralizes wild types of the most prevalent variants in BrazilSemantic proximity Read ↗

Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.Semantic proximity Read ↗

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patientsSemantic proximity Read ↗

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.Semantic proximity Read ↗

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodiesSemantic proximity Read ↗

Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited seraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.